A newly published industry analysis by Fact.MR estimates revenue from the global respiratory syncytial virus (RSV) diagnostics market to reach US$ 1.3 Bn by 2031, surging at a CAGR of 9%. Demand for RSV diagnostic kits & assays to remain high and reach a valuation of US$ 720 Mn by the end of 2031.
Amongst the many factors credited to accelerating demand for respiratory syncytial virus diagnostics is rising burden of RSV infections, growing demand for molecular diagnostic tests, and increasing approvals of RSV diagnostic kits & assays.
Request Sample https://www.factmr.com/connectus/sample?flag=S&rep_id=6736
- Market Estimates and Forecasts (2016-2031)
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- COVID-19 Impact on Demand for Respiratory Syncytial Virus Diagnostics and How to Navigate
- Recommendation on Key Winning Strategies
Request Customization https://www.factmr.com/connectus/sample?flag=RC&rep_id=6736
The market for respiratory syncytial virus diagnostics grew from US$ 575 Mn in 2017 to US$ 678 Mn in 2020, and is anticipated to top US$ 1.3 Bn by 2031.
Respiratory syncytial virus is a very common and contagious virus that infects the respiratory track of most children before 1-2 years of age. RSV is the most common cause of bronchiolitis and pneumonia. It also causes respiratory illness in adults, and it can occasionally cause serious infection that needs hospitalization due to breathing complications with bronchiolitis or pneumonia.
For diagnosis, doctors mostly rely on a blood or urine test to look for bacterial infection, chest X-ray for checking any signs of pneumonia, and a test of material scraped out from the patient’s nose or mouth.
Globally, cases of RSV infections are on the rise, which is fuelling demand for rapid diagnostic techniques. According to the Centre of Disease Control and Prevention (CDC), each year, on an average, RSV leads to the hospitalizations of around 1,32,000 – 1,72,000 children below the age of five, and the death of around 14,000 adults above the age of 65, in the United States alone.
As the clinical symptoms of RSV infections are indistinguishable from other respiratory infections, there is growing need for rapid, specific, and sensitive diagnostic techniques.
New technologies such as filament-based antibody detection assays, thin layer-based amperometric enzyme immunoassay (EIA), and multiplex virus testing are in the final stage of development.
Furthermore, nucleic acid amplification techniques and loop-mediated isothermal amplification will soon be aligned with point of care (POC) devices. This will allow testing to be performed using a one-step kit, which will require only the addition of a patient sample.
Also, the nanoparticle technology, which has the potential to bring about a four-fold improvement in viral detection as compared to RT-PCR, is under development.
Similarly, plasmonic detection techniques such as localized surface plasmon resonance (LSPR) spectroscopy (which uses metallic nanomaterials by exploiting physicochemical peculiarities) are under development with POC detection devices.
This is considered as a major development as methods such as LSPR spectroscopy offer rapid diagnostics and superior sensitivity & affordability as compared to techniques such as surface-enhanced Raman spectroscopy (SERS) and Polymerase Chain Reaction (PCR) coupled with electrospray ionization mass spectrometry (PCR-ESI-MS), which are not cost-effective, cumbersome to perform, and are more limited to research purposes.
Over the next few years, all the above-mentioned technologies are expected to be included in commercialized diagnostic methods. This is considered as a potential growth area for players involved in RSV diagnostics.
Key Market Segments Covered in Respiratory Syncytial Virus Diagnostics Industry Research
- By Technology
- RSV Molecular Diagnostics
- RSV Monoclonal Antibodies
- Differential Light Scattering
- Artificial Intelligence
- Flow Cytometry
- Diagnostic Imaging
- Gel Microdroplets
- By End Users
- Respiratory Syncytial Virus Diagnostics at Hospitals
- Respiratory Syncytial Virus Diagnostics at Nursing Homes
- Respiratory Syncytial Virus Diagnostics at Commercial Laboratories
- Respiratory Syncytial Virus Diagnostics at Public Health Laboratories
The respiratory syncytial virus diagnostics landscape is highly fragmented in nature. Manufacturers are focusing on technological innovations for speeding up the diagnosis of the respiratory syncytial virus.
Frequent mergers and acquisitions also take place in the market. The acquisition of Sigma Aldrich by Merck KGaA is a classic example.
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583